| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
62,030,000 |
| Market
Cap: |
903.16(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$4.48 - $21.47 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile MacroGenics is a biopharmaceutical company. Co.'s main pipeline program is MGC018, an antibody-drug conjugate that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Co. is also developing enoblituzumab, an Fc-optimized monoclonal antibody that targets B7-H3 and molecules that target programmed cell death protein 1, a protein that is important in the regulation of the immune system's response to cancer. In addition, Co. is developing MGD024, a bispecific DART molecule that engages CD3 on immune effector cells to kill CD123-expressing cancer cells in certain hematological malignancies, including acute myeloid leukemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
350,000 |
2,394,399 |
| Total Buy Value |
$0 |
$0 |
$1,722,425 |
$11,462,434 |
| Total People Bought |
0 |
0 |
1 |
2 |
| Total Buy Transactions |
0 |
0 |
2 |
11 |
| Total Shares Sold |
261,204 |
293,400 |
293,400 |
298,772 |
| Total Sell Value |
$4,645,136 |
$4,995,238 |
$4,995,238 |
$5,027,631 |
| Total People Sold |
5 |
5 |
5 |
5 |
| Total Sell Transactions |
9 |
11 |
11 |
12 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Cilinski Lynn |
VP, Controller and Treasurer |
• – – |
2015-07-01 |
4 |
AS |
$37.15 |
$257,115 |
D/D |
(6,921) |
3,844 |
|
- |
|
| Cilinski Lynn |
VP, Controller and Treasurer |
• – – |
2015-07-01 |
4 |
OE |
$0.94 |
$4,700 |
D/D |
5,000 |
10,765 |
|
- |
|
| Bonvini Ezio |
Senior VP, Research |
• – – |
2015-06-30 |
4 |
AS |
$38.07 |
$247,341 |
D/D |
(6,497) |
36,790 |
|
- |
|
| Bonvini Ezio |
Senior VP, Research |
• – – |
2015-06-30 |
4 |
OE |
$0.71 |
$4,613 |
D/D |
6,497 |
43,287 |
|
- |
|
| Bonvini Ezio |
Senior VP, Research |
• – – |
2015-06-24 |
4/A |
AS |
$38.08 |
$232,174 |
D/D |
(6,097) |
36,790 |
|
- |
|
| Bonvini Ezio |
Senior VP, Research |
• – – |
2015-06-24 |
4/A |
OE |
$0.71 |
$4,329 |
D/D |
6,097 |
42,887 |
|
- |
|
| Bonvini Ezio |
Senior VP, Research |
• – – |
2015-06-24 |
4 |
AS |
$38.08 |
$232,174 |
D/D |
(6,097) |
17,639 |
|
- |
|
| Bonvini Ezio |
Senior VP, Research |
• – – |
2015-06-23 |
4/A |
AS |
$38.14 |
$497,880 |
D/D |
(13,054) |
36,790 |
|
- |
|
| Bonvini Ezio |
Senior VP, Research |
• – – |
2015-06-23 |
4/A |
OE |
$0.71 |
$9,268 |
D/D |
13,054 |
49,844 |
|
- |
|
| Bonvini Ezio |
Senior VP, Research |
• – – |
2015-06-23 |
4 |
AS |
$38.14 |
$497,880 |
D/D |
(13,054) |
23,736 |
|
- |
|
| Cilinski Lynn |
VP, Controller and Treasurer |
• – – |
2015-06-15 |
4 |
AS |
$35.00 |
$374,500 |
D/D |
(10,700) |
5,765 |
|
- |
|
| Cilinski Lynn |
VP, Controller and Treasurer |
• – – |
2015-06-15 |
4 |
OE |
$0.94 |
$4,700 |
D/D |
5,000 |
16,465 |
|
- |
|
| Bonvini Ezio |
Senior VP, Research |
• – – |
2015-06-15 |
4 |
AS |
$34.01 |
$211,984 |
D/D |
(6,233) |
36,790 |
|
- |
|
| Bonvini Ezio |
Senior VP, Research |
• – – |
2015-06-15 |
4 |
OE |
$0.71 |
$4,425 |
D/D |
6,233 |
43,023 |
|
- |
|
| Bonvini Ezio |
Senior VP, Research |
• – – |
2015-05-15 |
4 |
AS |
$30.24 |
$188,486 |
D/D |
(6,233) |
36,790 |
|
- |
|
| Bonvini Ezio |
Senior VP, Research |
• – – |
2015-05-15 |
4 |
OE |
$0.71 |
$4,425 |
D/D |
6,233 |
43,023 |
|
- |
|
| Hurwitz Edward |
Director |
– • – |
2015-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
18,074 |
18,074 |
|
- |
|
| Saran Atul |
General Counsel |
• – – |
2015-04-28 |
4 |
D |
$32.02 |
$29,619 |
D/D |
(925) |
20,710 |
|
- |
|
| Bonvini Ezio |
Senior VP, Research |
• – – |
2015-04-15 |
4 |
AS |
$33.98 |
$211,797 |
D/D |
(6,233) |
36,790 |
|
- |
|
| Bonvini Ezio |
Senior VP, Research |
• – – |
2015-04-15 |
4 |
OE |
$0.71 |
$4,425 |
D/D |
6,233 |
43,023 |
|
- |
|
| Wigginton Jon Marc |
Sr VP, Clinical |
• – – |
2015-04-01 |
4 |
AS |
$30.86 |
$154,300 |
D/D |
(5,000) |
0 |
|
- |
|
| Wigginton Jon Marc |
Sr VP, Clinical |
• – – |
2015-02-02 |
4 |
AS |
$31.04 |
$155,200 |
D/D |
(5,000) |
0 |
|
- |
|
| Wigginton Jon Marc |
Sr VP, Clinical |
• – – |
2015-02-02 |
4 |
OE |
$4.70 |
$23,500 |
D/D |
5,000 |
5,000 |
|
- |
|
| Karrels James |
VP, CFO and Secretary |
• – – |
2014-12-24 |
4 |
OE |
$0.94 |
$3,854 |
D/D |
4,100 |
4,100 |
|
- |
|
| Stein Kathryn E |
SVP, Product Dev. & Regulatory |
• – – |
2014-12-22 |
4 |
AS |
$37.00 |
$405,002 |
D/D |
(10,946) |
43,205 |
|
- |
|
286 Records found
|
|
Page 10 of 12 |
|
|
0.19 (1.32%) 
